Will ritexitinib (Lefenox) affect menstruation and precautions for female medication?

Ritlecitinib (Ritlecitinib) is a targeted immunomodulatory drug mainly used to treat autoimmune diseases. In female patients, the menstrual cycle may be affected during medication. Some clinical studies and patient reports show that a small number of women experience prolonged menstrual cycles or changes in menstrual flow after using ritexitinib, but the overall incidence is low. Patients should explain their menstrual history and related gynecological diseases to the doctor in detail before taking the medicine.

For women of childbearing age, ritexitinib may have potential reproductive system effects, so doctors usually recommend a pregnancy test and discuss contraceptive options before starting the drug. Female patients should take effective contraceptive measures during the entire period of medication to prevent potential risks to the fetus. If the patient plans to become pregnant, he or she must stop taking the drug under the guidance of a doctor and wait for the drug to be completely eliminated from the body before conceiving.

During the course of medication, if female patients experience menstrual disorders, a significant increase or decrease in menstrual flow, or are accompanied by other gynecological discomforts, such as lower abdominal pain, abnormal bleeding, etc., they should seek medical treatment in time. The doctor may adjust the dosage of the medication based on symptoms, or discontinue and replace the medication if necessary. At the same time, regular monitoring of blood routine and liver function can also help evaluate the impact of drugs on the overall physical condition.

In short, when using ritexitinib in women, special attention should be paid to menstrual and reproductive health issues. Patients should maintain close communication with their doctors, record menstrual changes, and follow the doctor's instructions for regular examinations and medication adjustments to ensure the safety and effectiveness of treatment while reducing the risk of potential adverse reactions.

Reference materials:https://www.drugs.com/